Curileum Discovery Ltd

Curileum is a discovery stage company in London targeting defective mucosal stem cells that underpin serious gastrointestinal (GI) diseases and disorders with major GI complications.

Organisation type
Jeffrey Moore
Founder & CEO 

ImmuPharma plc

ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM). The company is focusing on developing novel medicines for specialist indications with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and over 70 patents. Forigerimod (P140 or Lupuzor™) is the company’s most advanced drug candidate for autoimmune diseases and is an immunomodulator, not an immunosuppressant. Lupuzor ™ received "Fast Track" designation from the US FDA and has recently completed a Phase III trial.

Forigerimod is a first-in-class peptide drug modulating autophagy.

ImmuPharma is based in London, U.K. and has three subsidiaries in France and one in Switzerland.

Dimitri Dimitriou
Chief Executive Officer 

Mereo BioPharma Group plc


Our mission is to provide new therapies to patients with chronically debilitating and life limiting rare diseases that have few, if any, other treatment options.

Our goal is to build an international biopharmaceutical company developing and commercializing new therapies for rare disease patients, focusing on bone/musculoskeletal, respiratory and endocrine indications.


Our clinical-stage, rare disease assets originated in pharmaceutical or biotechnology companies where for strategic reasons they were not being progressed. With the streamlined efficiency of a small company and with our internal expertise and external resources we are able to rapidly progress the products into late stage development and the planned subsequent commercialization. 

Donald Coppen
Director of Corporate Development 
Pascal Venn
Manager, Corporate Development 

Pneumagen Ltd

Pneumagen is using its platform technology, GlycoTarge™, to develop glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer.  

Pneumagen’s lead product, Neumifil™, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV) infections. When administered intranasally in preclinical models, Neumifil™ has demonstrated prevention, treatment and post-exposure prophylaxis of IFV and RSV infections with no observed toxicity. Pneumagen’s mCBM, in development for cancer, isknown as Neumonco™. In vitro data have demonstrated that mCBMs target and enter cancer cells, reducing cell proliferation, migration, metabolism and differentiation. A recent in vivo study demonstrates that Neumonco™ significantly inhibits tumour growth in an orthotopic mouse xenograft model of human ovarian cancer.

Founded in 2016, the Company is a spin-out start-up from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Please visit for more information.

Douglas Thomson